News . Data . Research
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) released details of discoveries that have potential applications for tumor suppression across multiple cancer pathways.
Cara Therapeutics Inc (NASDAQ:CARA) Q4 2022 Earnings Call dated Mar. 06, 2023. Corporate Participants: Chris Posner -- President and Chief Executive Officer Ryan Maynard -- Chief
Patterson Companies Inc (NASDAQ: PDCO) Q3 2023 earnings call dated Mar. 02, 2023 Corporate Participants: John Wright -- Vice President, Investor Relations Don Zurbay -- President
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q4 2022 Earnings Call dated Mar. 01, 2023. Corporate Participants: Darren Fox -- Executive Director, Investor Relations Bruce C. Cozadd -- Chairman
ImmunoGen Inc (NASDAQ:IMGN) Q4 2022 Earnings Call dated Mar. 01, 2023. Corporate Participants: Anabel Chan -- Head of Investor Relations Mark Enyedy -- President and Chief
Agilent Technologies (NYSE: A) has announced first-quarter 2023 financial results, reporting an increase in adjusted profit and revenues. The Santa Clara, California-based
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Atabak Mokari -- Chief Financial Officer Charles Robb -- Chief Business Officer
Novavax Inc (NASDAQ:NVAX) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Erika Schultz -- Senior Director of Investor Relations John Jacobs -- President and
Agilent Technologies Inc (NYSE:A) Q1 2023 Earnings Call dated Feb. 28, 2023. Corporate Participants: Parmeet Ahuja -- Investor Relations Mike McMullen -- President and Chief Executive
PetIQ Inc (NASDAQ:PETQ) Q4 2022 Earnings Call dated Feb. 28, 2023. Corporate Participants: Katie Turner -- Investor Relations McCord Christensen -- Chief Executive Officer and Chairman
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jonathan Kurtis received a new patent for his discovery related
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q4 2022 Earnings Call dated Feb. 27, 2023. Corporate Participants: Traci McCarty -- Group Vice President of Investor Relations Jean-Jacques
FibroGen Inc (NASDAQ:FGEN) Q4 2022 Earnings Call dated Feb. 27, 2023. Corporate Participants: Michael Tung -- Vice President, Corporate Strategy and Investor Relations Enrique
The global pharmaceutical market is expected to cross $1.5 trillion this year, which represents a 4-5% annual growth over the past five
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here’s a look at the company’s
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here are the company’s numbers for
Moderna Inc (NASDAQ:MRNA) Q4 2022 Earnings Call dated Feb. 23, 2023. Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive Officer
Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a
Medtronic PLC (NYSE: MDT) Q3 2023 earnings call dated Feb. 21, 2023 Corporate Participants: Ryan Weispfenning -- Vice President and Head of Investor Relations
Medtronic plc (NYSE: MDT) reported third quarter 2023 earnings results today. Revenue of $7.7 billion was flat as reported and up 4.1% organically compared
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q4 2022 earnings call dated Feb. 16, 2023 Corporate Participants: Matt Roache -- Director of Investor Relations Thomas McCourt -- Chief